Financhill
Sell
32

ENTA Quote, Financials, Valuation and Earnings

Last price:
$5.81
Seasonality move :
-0.34%
Day range:
$5.70 - $5.94
52-week range:
$4.09 - $17.24
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.92x
P/B ratio:
1.33x
Volume:
100.7K
Avg. volume:
156.2K
1-year change:
-51.62%
Market cap:
$124.4M
Revenue:
$67.6M
EPS (TTM):
-$4.54

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ENTA
Enanta Pharmaceuticals
$16M -$1.14 -9.79% -24.3% $14.83
IVF
INVO Fertility
$1.6M -- -8.8% -- --
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
OGEN
Oragenics
-- -- -- -- $1.00
PSTV
Plus Therapeutics
$1.1M -$0.29 -- -54.22% $9.83
TOVX
Theriva Biologics
-- -$1.56 -- -95.63% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ENTA
Enanta Pharmaceuticals
$5.82 $14.83 $124.4M -- $0.00 0% 1.92x
IVF
INVO Fertility
$1.65 -- $3.5M -- $0.00 0% 0.15x
NBY
NovaBay Pharmaceuticals
$0.57 $0.85 $3.3M -- $0.00 0% 0.16x
OGEN
Oragenics
$0.19 $1.00 $4.1M -- $0.00 0% 1.84x
PSTV
Plus Therapeutics
$0.29 $9.83 $4.9M -- $0.00 0% 0.36x
TOVX
Theriva Biologics
$0.46 $7.00 $3.7M -- $0.00 0% 0.33x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ENTA
Enanta Pharmaceuticals
-- -0.391 -- 5.09x
IVF
INVO Fertility
65.97% 3.433 20.29% 0.05x
NBY
NovaBay Pharmaceuticals
4.54% -0.186 1.51% 0.75x
OGEN
Oragenics
-- 3.254 -- --
PSTV
Plus Therapeutics
-- -0.140 -- --
TOVX
Theriva Biologics
-- -2.512 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ENTA
Enanta Pharmaceuticals
-- -$24.5M -74.26% -74.26% -148.97% -$16M
IVF
INVO Fertility
$592.3K -$2.5M -313.33% -714.24% -1044.01% -$3.6M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
PSTV
Plus Therapeutics
-- -$3.8M -- -- -- -$3.7M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M

Enanta Pharmaceuticals vs. Competitors

  • Which has Higher Returns ENTA or IVF?

    INVO Fertility has a net margin of -151.71% compared to Enanta Pharmaceuticals's net margin of -1063.02%. Enanta Pharmaceuticals's return on equity of -74.26% beat INVO Fertility's return on equity of -714.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    ENTA
    Enanta Pharmaceuticals
    -- -$1.06 $93.5M
    IVF
    INVO Fertility
    36.18% -$12.53 $9.8M
  • What do Analysts Say About ENTA or IVF?

    Enanta Pharmaceuticals has a consensus price target of $14.83, signalling upside risk potential of 154.87%. On the other hand INVO Fertility has an analysts' consensus of -- which suggests that it could grow by 263.64%. Given that INVO Fertility has higher upside potential than Enanta Pharmaceuticals, analysts believe INVO Fertility is more attractive than Enanta Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ENTA
    Enanta Pharmaceuticals
    2 2 0
    IVF
    INVO Fertility
    0 0 0
  • Is ENTA or IVF More Risky?

    Enanta Pharmaceuticals has a beta of 0.811, which suggesting that the stock is 18.902% less volatile than S&P 500. In comparison INVO Fertility has a beta of 2.243, suggesting its more volatile than the S&P 500 by 124.267%.

  • Which is a Better Dividend Stock ENTA or IVF?

    Enanta Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. INVO Fertility offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals pays -- of its earnings as a dividend. INVO Fertility pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ENTA or IVF?

    Enanta Pharmaceuticals quarterly revenues are $14.9M, which are larger than INVO Fertility quarterly revenues of $1.6M. Enanta Pharmaceuticals's net income of -$22.6M is lower than INVO Fertility's net income of -$17.4M. Notably, Enanta Pharmaceuticals's price-to-earnings ratio is -- while INVO Fertility's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals is 1.92x versus 0.15x for INVO Fertility. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ENTA
    Enanta Pharmaceuticals
    1.92x -- $14.9M -$22.6M
    IVF
    INVO Fertility
    0.15x -- $1.6M -$17.4M
  • Which has Higher Returns ENTA or NBY?

    NovaBay Pharmaceuticals has a net margin of -151.71% compared to Enanta Pharmaceuticals's net margin of -49.65%. Enanta Pharmaceuticals's return on equity of -74.26% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    ENTA
    Enanta Pharmaceuticals
    -- -$1.06 $93.5M
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About ENTA or NBY?

    Enanta Pharmaceuticals has a consensus price target of $14.83, signalling upside risk potential of 154.87%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 50.23%. Given that Enanta Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Enanta Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ENTA
    Enanta Pharmaceuticals
    2 2 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is ENTA or NBY More Risky?

    Enanta Pharmaceuticals has a beta of 0.811, which suggesting that the stock is 18.902% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

  • Which is a Better Dividend Stock ENTA or NBY?

    Enanta Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ENTA or NBY?

    Enanta Pharmaceuticals quarterly revenues are $14.9M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Enanta Pharmaceuticals's net income of -$22.6M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Enanta Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals is 1.92x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ENTA
    Enanta Pharmaceuticals
    1.92x -- $14.9M -$22.6M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns ENTA or OGEN?

    Oragenics has a net margin of -151.71% compared to Enanta Pharmaceuticals's net margin of --. Enanta Pharmaceuticals's return on equity of -74.26% beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ENTA
    Enanta Pharmaceuticals
    -- -$1.06 $93.5M
    OGEN
    Oragenics
    -- -$0.12 --
  • What do Analysts Say About ENTA or OGEN?

    Enanta Pharmaceuticals has a consensus price target of $14.83, signalling upside risk potential of 154.87%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 420.83%. Given that Oragenics has higher upside potential than Enanta Pharmaceuticals, analysts believe Oragenics is more attractive than Enanta Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ENTA
    Enanta Pharmaceuticals
    2 2 0
    OGEN
    Oragenics
    0 1 0
  • Is ENTA or OGEN More Risky?

    Enanta Pharmaceuticals has a beta of 0.811, which suggesting that the stock is 18.902% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

  • Which is a Better Dividend Stock ENTA or OGEN?

    Enanta Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ENTA or OGEN?

    Enanta Pharmaceuticals quarterly revenues are $14.9M, which are larger than Oragenics quarterly revenues of --. Enanta Pharmaceuticals's net income of -$22.6M is lower than Oragenics's net income of -$2.2M. Notably, Enanta Pharmaceuticals's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals is 1.92x versus 1.84x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ENTA
    Enanta Pharmaceuticals
    1.92x -- $14.9M -$22.6M
    OGEN
    Oragenics
    1.84x -- -- -$2.2M
  • Which has Higher Returns ENTA or PSTV?

    Plus Therapeutics has a net margin of -151.71% compared to Enanta Pharmaceuticals's net margin of --. Enanta Pharmaceuticals's return on equity of -74.26% beat Plus Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ENTA
    Enanta Pharmaceuticals
    -- -$1.06 $93.5M
    PSTV
    Plus Therapeutics
    -- -$0.37 --
  • What do Analysts Say About ENTA or PSTV?

    Enanta Pharmaceuticals has a consensus price target of $14.83, signalling upside risk potential of 154.87%. On the other hand Plus Therapeutics has an analysts' consensus of $9.83 which suggests that it could grow by 3277.99%. Given that Plus Therapeutics has higher upside potential than Enanta Pharmaceuticals, analysts believe Plus Therapeutics is more attractive than Enanta Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ENTA
    Enanta Pharmaceuticals
    2 2 0
    PSTV
    Plus Therapeutics
    1 1 0
  • Is ENTA or PSTV More Risky?

    Enanta Pharmaceuticals has a beta of 0.811, which suggesting that the stock is 18.902% less volatile than S&P 500. In comparison Plus Therapeutics has a beta of 0.878, suggesting its less volatile than the S&P 500 by 12.185%.

  • Which is a Better Dividend Stock ENTA or PSTV?

    Enanta Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals pays -- of its earnings as a dividend. Plus Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ENTA or PSTV?

    Enanta Pharmaceuticals quarterly revenues are $14.9M, which are larger than Plus Therapeutics quarterly revenues of --. Enanta Pharmaceuticals's net income of -$22.6M is lower than Plus Therapeutics's net income of -$2.9M. Notably, Enanta Pharmaceuticals's price-to-earnings ratio is -- while Plus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals is 1.92x versus 0.36x for Plus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ENTA
    Enanta Pharmaceuticals
    1.92x -- $14.9M -$22.6M
    PSTV
    Plus Therapeutics
    0.36x -- -- -$2.9M
  • Which has Higher Returns ENTA or TOVX?

    Theriva Biologics has a net margin of -151.71% compared to Enanta Pharmaceuticals's net margin of --. Enanta Pharmaceuticals's return on equity of -74.26% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ENTA
    Enanta Pharmaceuticals
    -- -$1.06 $93.5M
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About ENTA or TOVX?

    Enanta Pharmaceuticals has a consensus price target of $14.83, signalling upside risk potential of 154.87%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1438.46%. Given that Theriva Biologics has higher upside potential than Enanta Pharmaceuticals, analysts believe Theriva Biologics is more attractive than Enanta Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ENTA
    Enanta Pharmaceuticals
    2 2 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is ENTA or TOVX More Risky?

    Enanta Pharmaceuticals has a beta of 0.811, which suggesting that the stock is 18.902% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

  • Which is a Better Dividend Stock ENTA or TOVX?

    Enanta Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ENTA or TOVX?

    Enanta Pharmaceuticals quarterly revenues are $14.9M, which are larger than Theriva Biologics quarterly revenues of --. Enanta Pharmaceuticals's net income of -$22.6M is lower than Theriva Biologics's net income of -$4.3M. Notably, Enanta Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals is 1.92x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ENTA
    Enanta Pharmaceuticals
    1.92x -- $14.9M -$22.6M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Palo Alto Networks Stock Be in 5 Years?
Where Will Palo Alto Networks Stock Be in 5 Years?

You know those companies that just refuse to slow down…

UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?
UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?

Parcel delivery giant UPS (NYSE:UPS) has seen its fair share…

Where Will Coinbase Stock Be in 5 Years?
Where Will Coinbase Stock Be in 5 Years?

If you’ve been anywhere near the crypto world over the…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
68
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
84
SBET alert for May 28

SharpLink Gaming [SBET] is up 454.46% over the past day.

Buy
58
TNXP alert for May 28

Tonix Pharmaceuticals Holding [TNXP] is up 27.51% over the past day.

Sell
37
ATS alert for May 28

ATS [ATS] is up 19.57% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock